Ozmosi | iN1012-N17 Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

iN1012-N17

Alternative Names: iN1012-N17, iN1012 N17, iN1012N17
Clinical Status: Active
Latest Update: 2023-10-23
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: NaV1.7 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: iN Therapeutics
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 0: Pain Unspecified

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title